Latest News and Press Releases

Autolus announces its operational and financial results for the first quarter ended March 31, 2025.

Novel, oral candidate with first-in-class potential progresses to regulatory non-clinical studies to support a Clinical Trial Authorisation First indication will be psoriatic arthritis, a...

Autolus presented updates on its development pipeline and plans for expansion in autoimmune diseases at an R&D investor event.

Autolus announces recent updates and financial results for the full year ended December 31, 2024.

Sitryx initiates Phase 1 clinical trial of potential disease-modifying treatment for atopic dermatitis SYX-5219 SYX-5219 is a first-in-class oral PKM2 modulator designed to drive sustained disease...

Alumis to Present at Leerink's 2025 Global Healthcare Conference

CARLSBAD, Calif., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Exagen Inc., a leading provider of autoimmune testing, today announced the completion of its 1,000,000th AVISE CTD test, marking a significant...

Remedy Plan Therapeutics Showcases at 2024 ASH Annual Meeting, Synergy Between RPT1G and Venetoclax

Remedy Plan Therapeutics Showcases at 2024 ASH Annual Meeting, Synergy Between RPT1G and Venetoclax

Company is evaluating IMSB301 in a Phase 1 clinical trial in healthy volunteers and plans to move rapidly into Phase 1b/2 clinical studies in patients with AGS, lupus and other cGAS-driven diseases ...